DrugPatentWatch Database Preview
Gemfibrozil - Generic Drug Details
What are the generic sources for gemfibrozil and what is the scope of gemfibrozil freedom to operate?
Gemfibrozil
is the generic ingredient in two branded drugs marketed by Mylan, Purepac Pharm, Pfizer Pharms, Apotex, Aurobindo Pharma Ltd, Cadila Pharms Ltd, Caribe Holdings, Chartwell Molecules, Hikma Pharms, Impax Pharms, Invagen Pharms, Northstar Hlthcare, Sun Pharm Inds Inc, Teva, Watson Labs, Yaopharma Co Ltd, and Zydus Pharms Usa Inc, and is included in twenty NDAs. Additional information is available in the individual branded drug profile pages.Forty-seven suppliers are listed for this compound. There is one tentative approval for this compound.
Summary for gemfibrozil
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 17 |
| NDAs: | 20 |
| Suppliers / Packagers: | 47 |
| Bulk Api Vendors: | 91 |
| Clinical Trials: | 35 |
| Patent Applications: | 6,275 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for gemfibrozil |
| DailyMed Link: | gemfibrozil at DailyMed |
Pharmacology for gemfibrozil
| Drug Class | Peroxisome Proliferator Receptor alpha Agonist |
| Mechanism of Action | Peroxisome Proliferator-activated Receptor alpha Agonists |
Medical Subject Heading (MeSH) Categories for gemfibrozil
Synonyms for gemfibrozil
| 1A Brand of Gemfibrozil |
| 2,2-Dimethyl-5-(2,5-dimethylphenoxy)-pentanoic acid |
| 2,2-Dimethyl-5-(2,5-dimethylphenoxy)pentanoic acid |
| 2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansaeure |
| 2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeric Acid |
| 2,2-Dimethyl-5-(2,5-xylyloxy)valeriansaeure |
| 2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid |
| 2,2-Dimethyl-5-(2,5-zlyloxy)valeric acid |
| 25812-30-0 |
| 4TX |
| 5-(2,5-Dimethyl-Phenoxy)-2,2-Dimethyl-Pentanoic Acid |
| 5-(2,5-dimethylphenoxy)-2,2-dimethyl-pentanoic acid |
| 5-(2,5-Dimethylphenoxy)-2,2-dimethylpentanoic acid |
| 5-(2,5-DIMETHYLPHYLPHENOXY)-2,2-DIMETHYLPENTANOIC ACID |
| 5-[(2,5-dimethylphenyl)oxy]-2,2-dimethylpentanoic acid |
| A0G461 |
| A818037 |
| AB00052003 |
| AB00052003_17 |
| AB00052003_18 |
| AB00052003-15 |
| AB00052003-16 |
| AB0013344 |
| AB03034 |
| AB2000253 |
| AC-4225 |
| AC1L1FZT |
| AC1Q2JC7 |
| AKOS001606691 |
| Alphapharm Brand of Gemfibrozil |
| AN-12208 |
| API0002816 |
| Apo Gemfibrozil |
| Apo-Gemfibrozil |
| ApoGemfibrozil |
| Apotex Brand of Gemfibrozil |
| ARONIS24091 |
| Ausgem |
| AX8032912 |
| Bayvit Brand of Gemfibrozil |
| Bayvit, Gemfibrozilo |
| BB_SC-04837 |
| BB_SC-4837 |
| BBC/228 |
| BBL010807 |
| BDBM50110590 |
| Bexal Brand of Gemfibrozil |
| BG0205 |
| Biochemie Brand of Gemfibrozil |
| Bolutol |
| BPBio1_000251 |
| BRD-K11129031-001-05-1 |
| BRN 1881200 |
| Brozil |
| BSPBio_000227 |
| BSPBio_002060 |
| Bull Brand of Gemfibrozil |
| C-15436 |
| C07020 |
| Cantabria Brand of Gemfibrozil |
| CAS-25812-30-0 |
| CC-28946 |
| CCG-40111 |
| CCRIS 318 |
| CG0035 |
| CHEBI:5296 |
| Chem mart Brand of Gemfibrozil |
| Chem mart Gemfibrozil |
| CHEMBL457 |
| Cholespid |
| CI 719 |
| CI-719 |
| CI719 |
| Clearol |
| CPD000058393 |
| CS-2244 |
| D00334 |
| D05VIX |
| DB01241 |
| DBL Gemfibrozil |
| Decrelip |
| DivK1c_000138 |
| DL-414 |
| Douglas Brand of Gemfibrozil |
| DR000672 |
| DSSTox_CID_652 |
| DSSTox_GSID_20652 |
| DSSTox_RID_75712 |
| DTXSID0020652 |
| EINECS 247-280-2 |
| Elmogan |
| Farmasierra Brand of Gemfibrozil |
| Faulding Brand of Gemfibrozil |
| Ferrer Brand of Gemfibrozil |
| Fetinor |
| Fibratol |
| Fibrocit |
| FT-0626641 |
| FT-0700924 |
| G0368 |
| Gem-S |
| Gemcor |
| Gemcor, Lopid, Jezil,Gen-Fibro, Gemfibrozil |
| Gemcor;Jezil;Gen-Fibro;Lopid |
| Gemd |
| Gemfi 1A Pharma |
| Gemfibril |
| Gemfibromax |
| Gemfibrosil |
| Gemfibrozil (JAN/USP/INN) |
| Gemfibrozil (Lopid) |
| GEMFIBROZIL (SEE ALSO PEROXISOME PROJECT (GEMFIBROZIL)) |
| Gemfibrozil [USAN:BAN:INN] |
| Gemfibrozil [USAN:USP:INN:BAN] |
| Gemfibrozil for system suitability, European Pharmacopoeia (EP) Reference Standard |
| Gemfibrozil, analytical standard |
| Gemfibrozil, British Pharmacopoeia (BP) Reference Standard |
| Gemfibrozil, European Pharmacopoeia (EP) Reference Standard |
| Gemfibrozil, GenRX |
| Gemfibrozil, Healthsense |
| Gemfibrozil, pharmaceutical secondary standard; traceable to USP, PhEur and BP |
| Gemfibrozil, SBPA |
| Gemfibrozil, United States Pharmacopeia (USP) Reference Standard |
| Gemfibrozilo |
| Gemfibrozilo [INN-Spanish] |
| Gemfibrozilo Bayvit |
| Gemfibrozilo Bexal |
| Gemfibrozilo Ur |
| Gemfibrozilum |
| Gemfibrozilum [INN-Latin] |
| Gemhexal |
| Gemlipid |
| Gemnpid |
| Gen Gemfibrozil |
| Gen-Fibro |
| Gen-Fibro (TN) |
| Gen-Gemfibrozil |
| GenGemfibrozil |
| Genlip |
| Genpharm Brand of Gemfibrozil |
| GenRX Gemfibrozil |
| Gevilon |
| Gevilon Uno |
| GFZ |
| Gozid |
| GP1460 |
| GTPL3439 |
| H900 |
| Healthsense Brand of Gemfibrozil |
| Healthsense Gemfibrozil |
| HEMJJKBWTPKOJG-UHFFFAOYSA-N |
| Hexal Brand of Gemfibrozil |
| Hidil |
| Hipolixan |
| HMS1568L09 |
| HMS1920B07 |
| HMS2090K14 |
| HMS2091H11 |
| HMS2095L09 |
| HMS2230H24 |
| HMS3259M12 |
| HMS3655C06 |
| HMS500G20 |
| HSDB 7735 |
| HY-B0258 |
| I01-1855 |
| IDI1_000138 |
| Innogem |
| Innogen |
| Ipolipid |
| Ipsen Brand of Gemfibrozil |
| J10068 |
| Jezil |
| Jezil (TN) |
| KBio1_000138 |
| KBio2_001305 |
| KBio2_003873 |
| KBio2_006441 |
| KBio3_001280 |
| KBioGR_000964 |
| KBioSS_001305 |
| KS-00000VK6 |
| KS-000046JO |
| KS-5192 |
| Lanaterom |
| Lifibron |
| Lipazil |
| Lipigem |
| Lipira |
| Lipizyl |
| Lipox Gemfi |
| Lipozid |
| Lipur |
| Litarek |
| Lopid |
| Lopid (TN) |
| Lopid R |
| lopizid |
| Low-Lip |
| LS-1085 |
| MCULE-4563546953 |
| Menarini Brand of Gemfibrozil |
| MFCD00079335 |
| Micolip |
| MLS000028421 |
| MLS001055364 |
| MLS006011850 |
| MolPort-001-794-413 |
| NC00565 |
| NCGC00016794-01 |
| NCGC00016794-02 |
| NCGC00016794-03 |
| NCGC00016794-04 |
| NCGC00016794-05 |
| NCGC00016794-06 |
| NCGC00016794-07 |
| NCGC00016794-08 |
| NCGC00016794-09 |
| NCGC00016794-10 |
| NCGC00016794-11 |
| NCGC00016794-13 |
| NCGC00016794-14 |
| NCGC00022722-03 |
| NCGC00022722-04 |
| NCGC00022722-05 |
| NCGC00022722-06 |
| NCGC00022722-07 |
| NCGC00256601-01 |
| NCGC00259546-01 |
| NINDS_000138 |
| Normolip |
| Novo Gemfibrozil |
| Novo-Gemfibrozil |
| Novopharm Brand of Gemfibrozil |
| NSC-757024 |
| NSC757024 |
| Nu Gemfibrozil |
| Nu Pharm Brand of Gemfibrozil |
| Nu-Gemfibrozil |
| Nu-Pharm Brand of Gemfibrozil |
| NuGemfibrozil |
| Opera_ID_1658 |
| OR249362 |
| Parke Davis Brand of Gemfibrozil |
| Pentanoic acid, 5-(2,5-dimethylphenoxy)-2,2-dimethyl- |
| PEROXISOME PROJECT (GEMFIBROZIL) (SEE ALSO GEMFIBROZIL) |
| Pfizer Brand of Gemfibrozil |
| Pharmakon1600-10500313 |
| Pharmascience Brand of Gemfibrozil |
| Pilder |
| PMS Gemfibrozil |
| PMS-Gemfibrozil |
| Polyxit |
| Prestwick_637 |
| Prestwick0_000214 |
| Prestwick1_000214 |
| Prestwick2_000214 |
| Prestwick3_000214 |
| Progemzal |
| Q8X02027X3 |
| Quimifar Brand of Gemfibrozil |
| Reducel |
| Regulip |
| Renabrazin |
| s1729 |
| SAM002564211 |
| SBB012457 |
| SBI-0051391.P003 |
| SBPA Gemfibrozil |
| SC-17669 |
| SCHEMBL4813 |
| SEL11160931 |
| Sigma Brand of Gemfibrozil |
| Sinelip |
| SMR000058393 |
| SPBio_001174 |
| SPBio_002148 |
| Spectrum_000825 |
| SPECTRUM1500313 |
| Spectrum2_001097 |
| Spectrum3_000440 |
| Spectrum4_000562 |
| Spectrum5_000750 |
| Spectrum5_001991 |
| SR-01000000056 |
| SR-01000000056-3 |
| SR-01000000056-6 |
| ST072198 |
| STK618740 |
| Synbrozil |
| Taborcil |
| TAD Brand of Gemfibrozil |
| Tentroc |
| Terry White Chemists Brand of Gemfibrozil |
| Terry White Chemists Gemfibrozil |
| TEVA-A |
| TL8002081 |
| Tox21_110613 |
| Tox21_110613_1 |
| Tox21_201997 |
| Tox21_302784 |
| Trialmin |
| UNII-Q8X02027X3 |
| United Drug Brand of Gemfibrozil |
| VA11004 |
| Valeric acid, 2,2-dimethyl-5-(2,5-xylyloxy)- |
| W-107216 |
| Warner Lambert Brand of Gemfibrozil |
| Warner-Lambert Brand of Gemfibrozil |
| WL-Gemfibrozil |
| Z-0832 |
| ZINC1530641 |
| ZX-AS004442 |
Tentative approvals for GEMFIBROZIL
| Applicant | Application No. | Strength | Dosage Form |
| ➤ Try a Free Trial | ➤ Try a Free Trial | 300MG | CAPSULE;ORAL |
US Patents and Regulatory Information for gemfibrozil
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer Pharms | LOPID | gemfibrozil | TABLET;ORAL | 018422-003 | Nov 20, 1986 | AB | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
| Pfizer Pharms | LOPID | gemfibrozil | CAPSULE;ORAL | 018422-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Purepac Pharm | GEMFIBROZIL | gemfibrozil | CAPSULE;ORAL | 072929-001 | Jan 29, 1993 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Aurobindo Pharma Ltd | GEMFIBROZIL | gemfibrozil | TABLET;ORAL | 202726-001 | Sep 16, 2015 | AB | RX | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for gemfibrozil
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer Pharms | LOPID | gemfibrozil | CAPSULE;ORAL | 018422-001 | Approved Prior to Jan 1, 1982 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Pfizer Pharms | LOPID | gemfibrozil | CAPSULE;ORAL | 018422-002 | Approved Prior to Jan 1, 1982 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2019 - 2020
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2019 - 2020
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.
Follow DrugPatentWatch: